Impact of Bkemv on AstraZeneca's stock price by end of 2024 | Categorical | | | 7 months ago | |
Bkemv achieves sales target in its first year? | Binary | | | 7 months ago | |
Another Soliris biosimilar approved by FDA in 2024? | Binary | | | 7 months ago | |
Number of new biosimilars for rare blood disorders approved in 2024 | Categorical | | | 7 months ago | |
Will Amgen's Bkemv reach $500 million in sales by May 2025? | Binary | | | 7 months ago | |
Will AstraZeneca's Soliris sales decline by more than 30% by May 2025? | Binary | | | 7 months ago | |
Will FDA approve additional indications for Amgen's Bkemv by May 2025? | Binary | | | 7 months ago | |
Market share outcomes for PNH and aHUS treatments by end of 2024 | Categorical | | | 7 months ago | |
AstraZeneca launches a new product for PNH and aHUS in 2024? | Binary | | | 7 months ago | |
How prevalent will Bkemv be in treating PNH and aHUS by May 2025? | Categorical | | | 7 months ago | |
Financial performance comparison between Amgen and AstraZeneca by end of 2025 | Categorical | | | 7 months ago | |
How will Amgen's stock price change by end of Q2 2025 post-Bkemv launch? | Categorical | | | 7 months ago | |
